Ceraxon [CDP Choline], solution 1000mg/4ml ampoules 5pcs

Composition

4 ml solution contains: Active ingredient: citicoline sodium (equivalent to 1000 mg of citicoline) excipients: 1 M hydrochloric acid or 1 M sodium hydroxide-up to pH 6.7-7.1; water for injection-up to 4 ml

Pharmacological action

Ceraxone is a nootropic drug.

Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action: promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, preventing excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis.

In the acute period of stroke, citicoline reduces the amount of damage to brain tissue, improves cholinergic transmission.

With traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, in addition, citicoline helps to reduce the duration of the recovery period.

In chronic brain hypoxia, citicoline is effective in the treatment of cognitive disorders such as memory loss, lack of initiative, difficulties in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia.

Ceraxon® is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.

Indications

• acute period of ischemic stroke (as part of complex therapy);
• recovery period of ischemic and hemorrhagic strokes;
• TBI, acute (as part of complex therapy) and recovery period;
• cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

Use during pregnancy and lactation

There are no sufficient data on the use of citicoline in pregnant women. Although no adverse effects have been identified in animal studies, Ceraxon® is prescribed during pregnancy only when the expected benefit to the mother outweighs the potential risk to the fetus.

When prescribing Ceraxon® during lactation, women should stop breastfeeding, since there are no data on the excretion of citicoline in human milk.

Contraindications

• hypersensitivity to any of the components of the drug;
• severe vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);
• rare hereditary diseases associated with fructose intolerance;
• children under 18 years of age (due to lack of sufficient clinical data).

Side effects

Very rare (less than 1/10000) (including individual cases): allergic reactions (rash, pruritus, anaphylactic shock), headache, dizziness, fever, tremor, nausea, vomiting, diarrhea, hallucinations, edema, shortness of breath, insomnia, agitation, decreased appetite, numbness in paralyzed limbs, changes in the activity of liver enzymes. In some cases, Ceraxone may stimulate the parasympathetic system, as well as cause a short-term change in blood pressure.

If any of the side effects listed in the instructions get worse, or any other side effects that are not listed in the instructions are noticed, you should inform your doctor.

The interaction of

Citicoline enhances the effects of levodopa.

Do not administer Ceraxone concomitantly with medications containing meclofenoxate.

How to take, course of use and dosage

Intravenously, the drug is administered as a slow injection (within 3-5 minutes, depending on the prescribed dose) or drip infusion (40-60 drops per minute). The intravenous route of use is preferable to intramuscular. When administered intramuscularly, repeated use of the drug in the same place should be avoided.

Acute period of ischemic stroke and traumatic brain injury: the recommended dose is 1000 mg every 12 hours from the first day after diagnosis; the duration of treatment is at least 6 weeks. In 3-5 days after the start of treatment (if swallowing function is not impaired), it is possible to switch to oral forms of Ceraxon®.

Recovery period for ischemic and hemorrhagic strokes, recovery period for traumatic brain injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: the recommended dose is 500-2000 mg/day (5-10 ml 1-2 times/day). The dose and duration of treatment depend on the severity of the symptoms of the disease.

Acute period of ischemic stroke and traumatic brain injury: the recommended dose is 1000 mg every 12 hours from the first day after diagnosis; the duration of treatment is at least 6 weeks. In 3-5 days after the start of treatment (if swallowing function is not impaired), it is possible to switch to oral forms of Ceraxon®.

Recovery period for ischemic and hemorrhagic strokes, recovery period for traumatic brain injury, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: the recommended dose is 500-2000 mg/day (5-10 ml 1-2 times/day). The dose and duration of treatment depend on the severity of the symptoms of the disease.

Overdose

Taking into account the low toxicity of the drug, cases of overdose are not described.

Special instructions

During the treatment period, care should be taken when performing potentially dangerous activities that require special attention and quick reactions (driving a car and other vehicles, working with moving mechanisms, working as a dispatcher and operator, etc. ).

Solution for oral use (optional). In the cold, a small amount of crystals may form due to temporary partial crystallization of the preservative. If further stored under the recommended conditions, the crystals dissolve within a few months. The presence of crystals does not affect the quality of the drug.

Form of production

Solution for injection.

Storage conditions

At a temperature not exceeding 30°C.

Shelf life

3 years

Active ingredient

Citicoline

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion

Description

For pregnant women as prescribed by a doctor, For adults as prescribed by a doctor

Indications

Concussion and other traumatic brain injuries, Acquired Dementia, Alzheimer’s Disease, Stroke effects